NCT02386501View on ClinicalTrials.gov

Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

April 30, 2017

Study Completion Date

September 30, 2018

Conditions
HER2 Expressing Solid Tumors
Interventions
DRUG

ADXS31-164

Trial Locations (6)

Unknown

Not Yet Recruiting, Los Angeles

Site, Aurora

Grand Rapids

Site, Charlotte

Site, Philadelphia

Dallas

Sponsors

Lead Sponsor

Advaxis, Inc.
All Listed Sponsors
lead

Advaxis, Inc.

INDUSTRY

NCT02386501 - Dose Escalation Study of ADXS31-164 in Subjects With HER2 Expressing Solid Tumors | Biotech Hunter | Biotech Hunter